Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics

Amicus Therapeutics, Inc. (FOLD): $11.78

0.08 (-0.67%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add FOLD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#57 of 363

in industry

FOLD Price/Volume Stats

Current price $11.78 52-week high $14.57
Prev. close $11.86 52-week low $9.70
Day low $11.49 Volume 2,475,945
Day high $11.93 Avg. volume 3,129,226
50-day MA $12.64 Dividend yield N/A
200-day MA $12.36 Market Cap 3.48B

FOLD Stock Price Chart Interactive Chart >

FOLD POWR Grades

  • FOLD scores best on the Growth dimension, with a Growth rank ahead of 93.23% of US stocks.
  • FOLD's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • FOLD ranks lowest in Momentum; there it ranks in the 18th percentile.

FOLD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FOLD is 2.79 -- better than 80.36% of US stocks.
  • With a price/sales ratio of 10.66, AMICUS THERAPEUTICS INC has a higher such ratio than 90.06% of stocks in our set.
  • FOLD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 82.25% of US stocks.
  • If you're looking for stocks that are quantitatively similar to AMICUS THERAPEUTICS INC, a group of peers worth examining would be EB, TBPH, DMRC, FUV, and PL.
  • Visit FOLD's SEC page to see the company's official filings. To visit the company's web site, go to www.amicusrx.com.

FOLD Valuation Summary

  • In comparison to the median Healthcare stock, FOLD's EV/EBIT ratio is 313.01% lower, now standing at -31.1.
  • FOLD's price/sales ratio has moved NA NA over the prior 202 months.

Below are key valuation metrics over time for FOLD.

Stock Date P/S P/B P/E EV/EBIT
FOLD 2023-12-29 11.2 31.2 -24.0 -31.1
FOLD 2023-12-28 11.4 32.0 -24.5 -31.8
FOLD 2023-12-27 11.4 31.8 -24.4 -31.6
FOLD 2023-12-26 11.1 31.0 -23.8 -30.9
FOLD 2023-12-22 10.7 29.9 -23.0 -29.8
FOLD 2023-12-21 10.4 29.0 -22.2 -28.9

FOLD Growth Metrics

    Its 2 year price growth rate is now at -42%.
  • Its 4 year net cashflow from operations growth rate is now at -80.01%.
  • The 5 year price growth rate now stands at 74.74%.
FOLD's revenue has moved up $41,468,000 over the prior 15 months.

The table below shows FOLD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 323.291 -156.317 -263.98
2022-06-30 321.145 -168.391 -280.988
2022-03-31 317.827 -188.452 -270.056
2021-12-31 305.514 -202.491 -250.46
2021-09-30 293.931 -181.799 -238.584
2021-06-30 281.823 -200.107 -252.301

FOLD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FOLD has a Quality Grade of C, ranking ahead of 63.39% of graded US stocks.
  • FOLD's asset turnover comes in at 0.333 -- ranking 138th of 680 Pharmaceutical Products stocks.
  • RDUS, CLVS, and NSTG are the stocks whose asset turnover ratios are most correlated with FOLD.

The table below shows FOLD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.333 0.884 -0.273
2021-03-31 0.323 0.884 -0.312
2020-12-31 0.323 0.881 -0.383
2020-09-30 0.308 0.884 -0.458
2020-06-30 0.286 0.886 -0.501
2020-03-31 0.246 0.883 -0.524

FOLD Price Target

For more insight on analysts targets of FOLD, see our FOLD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.90 Average Broker Recommendation 1.64 (Moderate Buy)

Amicus Therapeutics, Inc. (FOLD) Company Bio


Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.


FOLD Latest News Stream


Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream


Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks

It’s been a bountiful year for the stock market but that doesn’t mean there haven’t been laggards. The biotech industry, for example, has underperformed. While the Nasdaq Biotechnology Index (NBI) shows a 3% year-to-date gain, that is still some distance below the S&P 500’s 24% return. Therefore, with investor sentiment subdued, and some SMID-cap biotech firms still needing to raise capital against a challenging capital markets backdrop, Morgan Stanley’s Jeffrey Hung says the setup for SMID-cap

Yahoo | December 24, 2023

Amicus Therapeutics Inc's Chief Development Officer Sells Shares

On December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing.

Yahoo | December 21, 2023

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

BIO names longtime Amicus head John Crowley as new CEO

Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

Yahoo | December 5, 2023

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnolo

Yahoo | December 5, 2023

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo -14.95%
3-mo -16.98%
6-mo -3.13%
1-year 4.90%
3-year 28.04%
5-year -13.38%
YTD -16.98%
2023 16.22%
2022 5.71%
2021 -49.98%
2020 137.06%
2019 1.67%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!